Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The study addresses concerns about potential psychiatric side effects of Glucagon-like peptide-1 receptor agonists (GLP-1 RA). AIM: The aim of this work was to analyse adverse drug reports (ADRs) from the Food and Drug Administration Adverse Events Reporting System (FAERS) using metformin and orlistat as comparators. METHODS: Descriptive and pharmacovigilance disproportionality analyses was performed. RESULTS: A total of 209,354 ADRs were reported, including 59,300 serious cases. Of those, a total of 5378 psychiatric disorder cases, including 383 'serious' cases related to selected ADRs were registered during 2005-2023. After unmasking, 271 cases where individual GLP-1 RA were implicated showing liraglutide (n = 90; Reported Odds Ratio (ROR) = 1.64), exenatide (n = 67; ROR = 0.80), semaglutide (n = 61; ROR = 2.03), dulaglutide (n = 45; ROR = 0.84), tirzepatide (n = 5; ROR = 1.76) and albiglutide (n = 2; ROR = 0.04). A greater association between these ADRs with metformin was observed, but not orlistat. With regards to selected preferred terms (PTs), 42 deaths including 13 completed suicides were recorded. Suicidal ideation was recorded in n = 236 cases for 6/7 GLP-1 RA (excluding lixisenatide). DISCUSSION: Suicide/self-injury reports pertaining to semaglutide; tirzepatide; and liraglutide were characterised, although lower than metformin. It is postulated that rapid weight loss achieved with GLP-1 RA can trigger significant emotional, biological, and psychological responses, hence possibly impacting on suicidal and self-injurious ideations. CONCLUSIONS: With the current pharmacovigilance approach, no causality link between suicidal ideation and use of any GLP-1 RA can be inferred. There is a need for further research and vigilance in GLP-1 RA prescribing, particularly in patients with co-existing psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pories, W. J., Swanson, M. S., MacDonald, K. G., Long, S. B., Morris, P. G., Brown, B. M., Barakat, H. A., deRamon, R. A., Israel, G., Dolezal, J. M., et al. (1995) · Annals of Surgery · doi:10.1097/00000658-199509000-00011 · Cited by 2,293 · cited 5×
“More evidence is required to explore both the connection between post-RYGBP cognitive enhancement and GLP-1, and whether the post-surgery increase in GLP-1 may influence suicidality (Mitchell et al., 2013).”
BackgroundInfluentialEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“This led to its withdrawal from the market in several countries (Christensen et al., 2007).”
BackgroundDepression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073 · cited 1×
“Additionally, psychological factors like un-healthy coping mechanisms may play a role in the development and maintenance of obesity whilst also possibly impacting on mental health (Milaneschi et al., 2019; Lopresti and Drummond, 2013).”
BackgroundMuldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960 · cited 1×
“Since the early 1990s, there has been a growing interest in exploring cholesterol as a potential biomarker for suicide (Muldoon et al., 1990).”
BackgroundAthauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 1×
“Additionally, GLP-1 receptors interact with various neurotransmitter systems, including serotonin, dopamine, and glutamate (Athauda et al., 2017).”
BackgroundGLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510 · cited 2×
“…risk associated with GLP-1 RA may be tied to their impact on the hypothalamus (Drucker, 2022), considering the established association between the hyperactivity of the hypothalamic – pituitary – adrenal axis and the occurrence of suicidal behaviours (Drucker, 2022; Wis ł owska-Stanek et al., 2021).”
BackgroundGLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
Vagal and hormonal gut-brain communication: from satiation to satisfaction
Berthoud, H. ‐. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01104.x · Cited by 307 · cited 1×
“RYGBP is known to bring about substantial changes in gastrointestinal peptides, contributing to reduced appetite and enhanced satiation, thereby promoting weight loss (Berthoud, 2008).”
BackgroundA Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296 · cited 1×
“In addition, in preclinical studies, GLP-1 RA have been shown to cause an increased incidence of thyroid C-cell tumours in rodents (Butler et al., 2013).”
BackgroundNonpsychiatric Medical Treatment of Body Dysmorphic Disorder
Crerand, C. E., Phillips, K. A., Menard, W., & Fay, C. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.6.549 · Cited by 294
Research works printed but not linked: 36
- Ahrén, 2011, GLP-1 for type 2 diabetes, Exp. Cell Res., 317, 1239, 10.1016/j.yexcr.2011.01.010 · DOI
- Anderberg, 2014, Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior, Physiol. Behav., 136, 135, 10.1016/j.physbeh.2014.02.026 · DOI
- Baldini, 2023, The possible role of prescribing medications, including central nervous system drugs, in contributing to male-factor infertility (MFI): assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database, Brain Sci., 13, 1652, 10.3390/brainsci13121652 · DOI
- Bihan, 2020, Uses of pharmacovigilance databases: an overview, Therapies, 75, 591, 10.1016/j.therap.2020.02.022 · DOI · Paper page
- Boekholdt, 2010, Rimonabant: obituary for a wonder drug, Lancet, 376, 489, 10.1016/S0140-6736(10)61080-X · DOI
- Capogrosso Sansone, 2017, Muscular adverse drug reactions associated with proton pump inhibitors: a disproportionality analysis using the Italian national network of pharmacovigilance database, Drug Saf., 40, 895, 10.1007/s40264-017-0564-8 · DOI
- Chen, 2023, Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis, Eur. Psychiatry, 66, 10.1192/j.eurpsy.2023.2474 · DOI · Paper page
- Chiappini, S., Vickers-Smith, R., Papanti, D.G., Corkery, J.M., Guirguis, A., Martinotti, G., Sensi, S.L. and Schifano, F., 2023. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. 2023 Jul 11;16(7), 994. · DOI · Paper page
- Çiçekli, 2022, GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3β pathway, J. Recept. Signal Transduction Res., 42, 486, 10.1080/10799893.2022.2032747 · DOI
- Corazza, 2019, The emergence of Exercise Addiction, Body Dysmorphic Disorder, and other image-related psychopathological correlates in fitness settings: a cross-sectional study, PLoS ONE, 14, 10.1371/journal.pone.0213060 · DOI · Paper page
- Engelberg, 1992, Low serum cholesterol and suicide, Lancet, 339, 727, 10.1016/0140-6736(92)90609-7 · DOI · Paper page
- Faillie, 2019, Case–non-case studies: principles, methods, bias, and interpretation, Therapies, 74, 225, 10.1016/j.therap.2019.01.006 · DOI · Paper page
- Gawin, 1991, Cocaine addiction: psychology and neurophysiology, Science, 251, 1580, 10.1126/science.2011738 · DOI · Paper page
- Gawin, 1991, Correction: cocaine addiction: psychology and neuropsychology, Science, 253, 10.1126/science.253.5019.494.f · doi:10.1126/science.253.5019.494.f
- Gilbert, 2020, GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials, Front. Endocrinol. (Lausanne), 11, 178, 10.3389/fendo.2020.00178 · DOI · Paper page
- Hanna, 2015, The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health, Expert. Rev. Endocrinol. Metab., 10, 101, 10.1586/17446651.2015.972370 · DOI
- Isacson, 2011, The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test, Is Eur. J. Pharmacol., 650, 249, 10.1016/j.ejphar.2010.10.008 · DOI
- Ma, 2023, GLP-1 plays a protective role in hippocampal neuronal cells by activating cAMP-CREB-BDNF signaling pathway against CORT+HG-induced toxicity, Heliyon., 9, e18491, 10.1016/j.heliyon.2023.e18491 · DOI
- Maignen, 2014, Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases, Pharmacoepidemiol. Drug Saf., 23, 195, 10.1002/pds.3529 · doi:10.1002/pds.3529
- Mansur, 2018, Cognitive dysfunction and metabolic comorbidities in mood disorders: a repurposing opportunity for glucagon-like peptide 1 receptor agonists?, Neuropharmacology, 136, 335, 10.1016/j.neuropharm.2018.01.048 · DOI · Paper page
- Melis, 2007, The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food, Neurosci. Lett., 419, 231, 10.1016/j.neulet.2007.04.012 · DOI
- Mitchell, 2007, Depression and anxiety with rimonabant, Lancet, 370, 1671, 10.1016/S0140-6736(07)61705-X · DOI
- Mitchell, 2013, Possible risk factors for increased suicide following bariatric surgery, Obesity, 21, 665, 10.1002/oby.20066 · DOI · Paper page
- Montastruc, 2011, Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database, Br. J. Clin. Pharmacol., 72, 905, 10.1111/j.1365-2125.2011.04037.x · DOI · Paper page
- Nazeem, 2021, Saxagliptin ameliorated the depressive-like behavior induced by chronic unpredictable mild stress in rats: impact on incretins and AKT/PI3K pathway, Eur. J. Pharmacol., 912, 10.1016/j.ejphar.2021.174602 · DOI
- Phillips, 2007, Suicidality in body dysmorphic disorder, Prim. Psychiatry, 14, 58
- Robertson, 2009, Drugs associated with more suicidal ideations are also associated with more suicide attempts, PLoS ONE, 4, 10.1371/journal.pone.0007312 · DOI
- Ruggiero, 2024, Glucagon-like peptide-1 receptor agonists and suicidal ideation: analysis of real-word data collected in the European pharmacovigilance database, Pharmaceuticals, 17, 147, 10.3390/ph17020147 · DOI · Paper page
- Seo, 2023, Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test, J. Affect. Disord., 324, 8, 10.1016/j.jad.2022.12.089 · DOI · Paper page
- Sharma, 2015, GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats, Metab. Brain Dis., 30, 519, 10.1007/s11011-014-9591-7 · DOI · Paper page
- Tomson-Johanson, 2020, Low cholesterol levels in children predict impulsivity in young adulthood, Acta Neuropsychiatr., 32, 196, 10.1017/neu.2019.48 · DOI
- Van Gaal, 2008, Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program, Diabetes Care, 31, S229, 10.2337/dc08-s258 · DOI · Paper page
- Veale, 2001, Mirror, mirror on the wall, who is the ugliest of them all? The psychopathology of mirror gazing in body dysmorphic disorder, Behav. Res. Ther., 39, 1381, 10.1016/S0005-7967(00)00102-9 · DOI · Paper page
- Verovnik, 2024, Semaglutide, suicidal ideation and behaviour: a resting state functional magnetic resonance imaging perspective, Diabetes Obes. Metabol., 26, 10.1111/dom.15363 · DOI
- Wisłowska-Stanek, 2021, Neurobiological basis of increased risk for suicidal behaviour, Cells, 10, 2519, 10.3390/cells10102519 · DOI · Paper page
- Yau, 2013, Stress and eating behaviors, Minerva Endocrinol., 38, 255
Cited by
Shapiro, S. B., Yin, H., Yu, O. H. Y., Rej, S., Suissa, S., & Azoulay, L. (2025) · BMJ · doi:10.1136/bmj-2024-080679 · Cited by 49
Hurtado, I., Robles, C., Peiró, S., García-Sempere, A., & Sanfélix-Gimeno, G. (2024) · Diabetologia · doi:10.1007/s00125-024-06243-z · Cited by 45
Bushi, G., Khatib, M. N., Rohilla, S., Singh, M. P., Uniyal, N., Ballal, S., Bansal, P., Bhopte, K., Gupta, M., Gaidhane, A. M., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70037 · Cited by 27
Metadata
- Authors
- Guirguis, A., Chiappini, S., Papanti P, G., Vickers-Smith, R., Harris, D., Corkery, J., Arillotta, D., Floresta, G., Martinotti, G., & Schifano, F.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2024-05
- Volume
- 82
- Pages
- 82-91
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W4392936204
- Cited by
- 65
- References
- 22
- FWCI
- 49.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Swansea University
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. https://app.cochat.ai/papers/10.1016/j.euroneuro.2024.02.003
- The paper
- Guirguis, A., Chiappini, S., Papanti P, G., Vickers-Smith, R., Harris, D., Corkery, J., Arillotta, D., Floresta, G., Martinotti, G., & Schifano, F. (2024). Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2024.02.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.